查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球神經內分泌腫瘤治療市場——行業規模、份額、趨勢、競爭、機會、2018-2028 年預測、按產品分析、按站點分析、按最終用戶、按地區、按競爭對手
市場調查報告書
商品編碼
1244132

全球神經內分泌腫瘤治療市場——行業規模、份額、趨勢、競爭、機會、2018-2028 年預測、按產品分析、按站點分析、按最終用戶、按地區、按競爭對手

Neuroendocrine Tumor Treatment Market - Global Industry Size, Share, Trends, Competition, Opportunity and Forecast, 2018-2028 Segmented By Product Analysis, By Site Analysis, By End User, By Region and Competition
出版日期: | 出版商: TechSci Research | 英文 117 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球神經內分泌腫瘤治療市場預計將在 2024-2028 年的預測期內升級。

這是由於全球神經內分泌腫瘤的患病率不斷上升。 根據 2022 年 4 月的癌症雜誌文章“胃腸胰神經內分泌腫瘤 (GEP-NENs) 的診斷和治療管理進展”，神經內分泌腫瘤的發病率在過去 30 至 40 年中顯著增加。 1型神經纖維瘤病（NF1）、結節性硬化症（TSC）病、1型多發性內分泌腫瘤（MEN1）、2型多發性內分泌腫瘤（MEN2）、Von Hippel-Lindau綜合徵（VHL）神經內分泌腫瘤 (NET)。 根據 2022 年 2 月更新的最新美國臨床腫瘤學會神經內分泌腫瘤統計數據，在美國，每年有超過 12,000 人被診斷出患有神經內分泌腫瘤，約有 175,000 人患有神經內分泌腫瘤。

加大政府力度

美國等許多發達國家的政府都在為癌症研究尋求資金，以幫助診斷和治療癌症。 它還贊助了許多臨床試驗，以幫助公司開發癌症治療方法。 例如，截至 2021 年 4 月，對確保無癌未來至關重要的癌症研究的聯邦資助已從美國國家癌症研究所獲得約 1.1 億美元的研究資助。 此外，在 2021 年罕見癌症、罕見疾病和未滿足需求 (RCRDUN) 資助機會中，澳大利亞聯邦衛生部在 2022 年 1 月承諾撥款 6340 萬美元用於罕見癌症和罕見疾病的研究。我們宣布，我們已準備就緒. 此外，弗林德斯大學還獲得了 23.742 億美元的資金，其中包括用於“實施護士支持的共享護理模式以解決神經內分泌腫瘤患者未滿足的需求：AUS-NET 試驗”項目。 神經內分泌腫瘤研究基金會 (NETRF) 也投資了 150 萬美元用於開發先進的放射療法——□受體放射性核素療法 (PRRT)。

各公司採取的措施

該行業的許多參與者正在採用合作夥伴關係和協作、新產品發布、與分銷相關的協議以及地域擴張等戰略來確立其市場地位。 例如，2018 年 6 月，勃林格殷格翰宣布投資 2.7 億美元建設一個新的生物製劑開發中心 (BDC)，該中心不僅致力於免疫學，也致力於免疫腫瘤學。 此外，2018 年 1 月，Novartis AG 宣布從其子公司 Novartis Groupe France S.A. 購買所有普通股，包括 Advanced Accelerator Applications S.A. (AAA)。

近期發展

  • Aerium Therapeutics Inc 將於 2022 年 6 月開始運營，提供 2650 萬美元（2500 萬歐元）的資金用於低級別和高級神經內分泌腫瘤的系統靶向放射治療和診斷。
  • Ipsen SA 於 2022 年 3 月為 Somatuline Autogel/Somatuline Depot（蘭瑞□）投資了一款全新的最先進電子自動注射器，以推進該類別的創新並提升患者的給藥和注射體驗。底部。 這種自動注射器旨在改善類癌綜合徵、肢端肥大症或胃腸胰神經內分泌腫瘤患者的體驗。
  • Belzutifan (Welireg) 是一種缺氧誘導因子抑製劑，適用於患有 von Hippel-Lindau 病的成年人，於 2021 年 8 月獲得 FDA 批准。

市場細分

全球神經內分泌腫瘤治療市場根據產品分析、地點分析、最終用戶、地區和公司進行細分。 根據產品分析，市場可細分為生長抑素類似物 (SSA)、靶向療法等。 根據現場分析，市場分為肺、胰腺、結腸、小腸等。 基於最終用戶，市場分為醫院和診所、門診護理中心等。

公司簡介

在全球神經內分泌腫瘤治療市場上運營的主要競爭對手包括 F Hoffmann-La Roche AG、Bristol-Myers Squibb Co、Eli Lilly & Co、Novartis AG、Pfizer Inc、Amgen Inc、Exelixis Inc、Teva 這些包括 Pharmaceutical Industries Ltd、AVEO Pharmaceuticals Inc 和 Hutchison MediPharma Ltd.

報告範圍：

本報告將全球神經內分泌腫瘤市場分為以下幾類，以及下面詳述的行業趨勢：

神經內分泌腫瘤市場，按產品分析：

  • 生長抑素類似物 (SSA)
  • 靶向治療
  • 其他

神經內分泌腫瘤市場，網站分析：

  • 肺
  • 胰腺
  • 大腸
  • 小腸
  • 其他

最終用戶的神經內分泌腫瘤治療市場：

  • 醫院和診所
  • 門診中心
  • 其他

神經內分泌腫瘤治療市場，按地區劃分：

  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳大利亞
  • 歐洲
    • 法國
    • 德國
    • 英國
    • 意大利
    • 西班牙
  • 北美
    • 美國
    • 墨西哥
    • 加拿大
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥倫比亞
  • 中東和非洲
    • 南非
    • 沙特阿拉伯
    • 阿聯酋

競爭格局

公司概況：對全球神經內分泌腫瘤治療市場主要參與者的深入分析。

可自定義：

根據市場數據，TechSci Research 根據公司的具體需求提供定制服務。 該報告可以定制為：

公司信息

  • 對其他市場參與者（最多 5 家公司）進行深入分析和概況分析。

內容

第 1 章概述

  • 市場定義
  • 市場範圍
    • 目標市場
    • 研究目標年份
    • 主要市場細分

第二章研究方法論

  • 調查目的
  • 基線調查方法
  • 主要行業合作夥伴
  • 主要協會和次要信息
  • 調查方法
  • 數據三角測量和驗證
  • 假設和限制

第 3 章執行摘要

  • 市場概覽
  • 主要市場細分概述
  • 主要市場參與者概覽
  • 主要地區/國家概覽
  • 市場驅動因素、挑戰和趨勢概述

第 4 章 VOC（客戶之聲）

第5章臨床試驗分析

  • 正在進行的臨床試驗
  • 已完成臨床試驗
  • 已完成臨床試驗
  • 管道細分（按開發階段）
  • 管道細分（按狀態
  • 管道故障，按站點分析
  • 按地區劃分的渠道細分
  • 臨床試驗熱圖

第 6 章神經內分泌腫瘤的全球市場展望

  • 市場規模和預測
    • 按價值觀
  • 市場份額和預測
    • 按產品分析（生長抑素類似物 (SSA)、靶向療法、其他）
    • 部位分析（肺、胰腺、大腸、小腸等）
    • 按最終用戶（醫院/診所、門診診所、其他）
    • 按地區
    • 按公司分類（2022 年）
  • 市場地圖
    • 按產品分析
    • 通過站點分析
    • 最終用戶
    • 按地區

第 7 章亞太地區神經內分泌腫瘤治療市場展望

  • 市場規模和預測
    • 按價值觀
  • 市場份額和預測
    • 按產品分析（生長抑素類似物 (SSA)、靶向療法、其他）
    • 部位分析（肺、胰腺、大腸、小腸等）
    • 按最終用戶（醫院/診所、門診診所、其他）
    • 按國家
  • 亞太地區：國家/地區分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳大利亞

第八章歐洲神經內分泌腫瘤藥物市場展望

  • 市場規模和預測
    • 按價值觀
  • 市場份額和預測
    • 按產品分析（生長抑素類似物 (SSA)、靶向療法、其他）
    • 部位分析（肺、胰腺、大腸、小腸等）
    • 按最終用戶（醫院/診所、門診診所、其他）
    • 按國家
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 意大利
    • 西班牙

第九章北美神經內分泌腫瘤藥物市場展望

  • 市場規模和預測
    • 按價值觀
  • 市場份額和預測
    • 按產品分析（生長抑素類似物 (SSA)、靶向療法、其他）
    • 部位分析（肺、胰腺、大腸、小腸等）
    • 按最終用戶（醫院/診所、門診診所、其他）
    • 按國家
  • 北美：國家/地區分析
    • 美國
    • 墨西哥
    • 加拿大

第10章南美神經內分泌腫瘤藥物市場展望

  • 市場規模和預測
    • 按價值觀
  • 市場份額和預測
    • 按產品分析（生長抑素類似物 (SSA)、靶向療法、其他）
    • 部位分析（肺、胰腺、大腸、小腸等）
    • 按最終用戶（醫院/診所、門診診所、其他）
    • 按國家
  • 南美洲：：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 11 章中東和非洲神經內分泌腫瘤藥物的市場前景

  • 市場規模和預測
    • 按價值觀
  • 市場份額和預測
    • 按產品分析（生長抑素類似物 (SSA)、靶向療法、其他）
    • 部位分析（肺、胰腺、大腸、小腸等）
    • 按最終用戶（醫院/診所、門診診所、其他）
    • 按國家
  • MEA：國家分析
    • 南非神經內分泌腫瘤藥物
    • 關於沙特阿拉伯神經內分泌腫瘤的治療
    • 阿聯酋神經內分泌腫瘤的治療

第 12 章市場動態

  • 司機
    • 新藥的開發和批准
    • 人工智能 (AI) 在治療技術中的應用
    • 政府和公司加大力度
  • 做
    • 昂貴的醫療費用
    • 治療的伴隨副作用
    • 嚴格的監管框架

第13章市場趨勢與發展

  • 未來患者援助計劃 (PAP)
  • 正在進行的臨床試驗和研發計劃
  • 採用下一代測序技術

第14章競爭格局

  • Business Overview
  • Company Snapshot
  • Products & Services
  • Financials（As Reported）
  • Recent Developments
  • SWOT Analysis
    • F Hoffmann-La Roche AG
    • Bristol-Myers Squibb Co
    • Eli Lilly & Co
    • Novartis AG
    • Pfizer Inc
    • Amgen Inc
    • Exelixis Inc
    • Teva Pharmaceutical Industries Ltd
    • AVEO Pharmaceuticals Inc
    • Hutchison MediPharma Ltd

第15章 戰略建議

簡介目錄
Product Code: 7606

Global neuroendocrine tumor treatment market is anticipated to escalate in the forecast period, 2024-2028. This can be attributed to the rising prevalence of neuroendocrine tumors across the globe. The incidence of neuroendocrine tumors has increased notably in the past three to four decades, according to an article published in the Journal of Cancers in April 2022, titled "Advances in the Diagnosis and Therapeutic Management of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs)". Neurofibromatosis type 1 (NF1), tuberous sclerosis complex (TSC) disease, multiple endocrine neoplasia type 1 (MEN1), multiple endocrine neoplasia type 2 (MEN2), and Von Hippel-Lindau syndrome (VHL) can be owed to the increased prevalence of neuroendocrine tumor (NET). In the United States, more than 12,000 people are diagnosed with a neuroendocrine tumor per year, and around 175,000 people are living with it, according to the most recent American Society of Clinical Oncology Neuroendocrine Tumor Statistics, which was updated in February 2022.

Carcinoid tumor, which typically manifests in the gastrointestinal tract (GIT) or the lungs, affects between 3,000 and 30,000 persons in the United States, according to data updated in November 2021 by the National Center for Advancing Translational Sciences - Genetic and Rare Diseases Information Center. The high frequency of neuroendocrine cancer patients worldwide is anticipated to contribute to the market's growth.

The treatment techniques for neuroendocrine tumors such as targeted therapy, radionuclide treatment, somatostatin analogs, immunotherapy, CAR-T-Cell therapy, INF α, trans arterial treatment, vaccines, bispecific antibodies, and cytotoxic chemotherapy of highly differentiated and low differentiated G1 and G2 GEP neuroendocrine tumor treatments (NETs) have also observed innovations in the past few years. This advancement in treatment techniques has led to a robust improvement in the growth of the neuroendocrine tumor treatment market. Furthermore, there has been a severe betterment in the survival rates of all neuroendocrine tumor treatments, according to a study published in the JAMA Oncology Journal in 2017.

Increased Government Initiatives

The governments of many developed nations like the United States are raising funds for research in cancer to assist in its diagnosis as well as treatment. The government is also funding numerous clinical trials to encourage companies to develop successful and effective cancer treatments. For instance, with federal government funding in cancer research, which is essential to assuring a future free of cancer, the American Institute for Cancer Research has financed almost USD110 million in research as of April 2021. Additionally, under the 2021 Rare Cancers, Rare Illnesses and Unmet Need (RCRDUN) grant opportunity, The Department of Health of the Commonwealth of Australia January 2022 announced the availability of a grant for the study of rare cancers and rare diseases for USD 63.4 million. Moreover, for the project "Implementing a Nurse-Enabled, Shared-Care Model to Address Unmet Needs of People with Neuroendocrine Tumor: the AUS-NET Trial," Flinders University specifically obtained USD 2,374,220.10 in funding. Also, USD 1.5 million was invested by The Neuroendocrine Tumor Research Foundation (NETRF) for the development of Peptide Receptor Radionuclide Therapy (PRRT), an advanced radiation therapy.

Steps were taken by the Companies

Plenty of players in the industry are also adopting strategies, for example, partnerships and collaborations, novel product launches, agreements related to distribution along with a regional extension to establish their market position. For example, Boehringer Ingelheim GmbH declared an investment of USD 270 million for the construction of a new Biologicals Development Center (BDC) that will be specializing in immunology as well as immune-oncology in June 2018. Additionally, Novartis AG, in January 2018 announced to buy of all the ordinary shares from its subsidiary group Novartis Groupe France S.A., also inclusive of Advanced Accelerator Applications S.A. (AAA).

Recent Developments

  • Aerium Therapeutics Inc began operations in June 2022 with USD26.50 million (EUR 25 million) funding for systemic targeted radiation therapy and the diagnosis of low- and high-grade neuroendocrine tumors.
  • Ipsen SA invested in a brand-new, cutting-edge electronic autoinjector in March 2022 for Somatuline Autogel/Somatuline Depot (lanreotide) to advance innovation in the category and enhance patient administration and injection experiences. The autoinjector is intended to enhance the patient experience for those dealing with carcinoid syndrome, acromegaly, or gastroenteropancreatic neuroendocrine tumors.
  • Belzutifan (Welireg), a hypoxia-inducible factor inhibitor suitable for adults suffering from von Hippel-Lindau disease received approval from FDA in August 2021.

Market Segmentation

Global neuroendocrine tumor treatment market is segmented based on a product analysis, site analysis, end user, region, and company. Based on a product analysis, the market can be categorized into somatostatin analogs (SSA), targeted therapy, and others. Based on site analysis, the market can be divided into lungs, pancreas, colon, small intestine, and others. Based on end users, the market can be segmented into hospitals & clinics, ambulatory care centers, and others.

Company Profiles

Some of the major competitors operating in the global neuroendocrine tumor treatment market are F Hoffmann-La Roche AG, Bristol-Myers Squibb Co, Eli Lilly & Co, Novartis AG, Pfizer Inc, Amgen Inc, Exelixis Inc, Teva Pharmaceutical Industries Ltd, AVEO Pharmaceuticals Inc, and Hutchison MediPharma Ltd among others.

Report Scope:

In this report, global neuroendocrine tumor market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Neuroendocrine Tumor Treatments Market, By Product Analysis:

  • Somatostatin Analogs (SSA)
  • Targeted Therapy
  • Others

Neuroendocrine Tumor Treatments Market, By Site Analysis:

  • Lungs
  • Pancreas
  • Colon
  • Small Intestine
  • Others

Neuroendocrine Tumor Treatments Market, By End User:

  • Hospitals & Clinics
  • Ambulatory Care Centers
  • Others

Neuroendocrine Tumor Treatments Market, By Region:

  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
  • Europe
    • France
    • Germany
    • United Kingdom
    • Italy
    • Spain
  • North America
    • United States
    • Mexico
    • Canada
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the global neuroendocrine Tumor treatment market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Clinical Trial Analysis

  • 5.1. Ongoing Clinical Trials
  • 5.2. Completed Clinical Trials
  • 5.3. Terminated Clinical Trials
  • 5.4. Breakdown of Pipeline, By Development Phase
  • 5.5. Breakdown of Pipeline, By Status
  • 5.6. Breakdown of Pipeline, By Site Analysis
  • 5.7. Breakdown of Pipeline, By Region
  • 5.8. Clinical Trials Heat Map

6. Global Neuroendocrine Tumor Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product Analysis (Somatostatin Analogs (SSA), Targeted Therapy, Others)
    • 6.2.2. By Site Analysis (Lungs, Pancreas, Colon, Small Intestine, Others)
    • 6.2.3. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
    • 6.2.4. By Region
    • 6.2.5. By Company (2022)
  • 6.3. Market Map
    • 6.3.1. By Product Analysis
    • 6.3.2. By Site Analysis
    • 6.3.3. By End User
    • 6.3.4. By Region

7. Asia-Pacific Neuroendocrine Tumor Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product Analysis (Somatostatin Analogs (SSA), Targeted Therapy, Others)
    • 7.2.2. By Site Analysis (Lungs, Pancreas, Colon, Small Intestine, Others)
    • 7.2.3. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
    • 7.2.4. By Country
  • 7.3. Asia-Pacific: Country Analysis
    • 7.3.1. China Neuroendocrine Tumor Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product Analysis
        • 7.3.1.2.2. By Site Analysis
        • 7.3.1.2.3. By End User
    • 7.3.2. India Neuroendocrine Tumor Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product Analysis
        • 7.3.2.2.2. By Site Analysis
        • 7.3.2.2.3. By End User
    • 7.3.3. Japan Neuroendocrine Tumor Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product Analysis
        • 7.3.3.2.2. By Site Analysis
        • 7.3.3.2.3. By End User
    • 7.3.4. South Korea Neuroendocrine Tumor Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product Analysis
        • 7.3.4.2.2. By Site Analysis
        • 7.3.4.2.3. By End User
    • 7.3.5. Australia Neuroendocrine Tumor Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product Analysis
        • 7.3.5.2.2. By Site Analysis
        • 7.3.5.2.3. By End User

8. Europe Neuroendocrine Tumor Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product Analysis (Somatostatin Analogs (SSA), Targeted Therapy, Others)
    • 8.2.2. By Site Analysis (Lungs, Pancreas, Colon, Small Intestine, Others)
    • 8.2.3. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
    • 8.2.4. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. France Neuroendocrine Tumor Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product Analysis
        • 8.3.1.2.2. By Site Analysis
        • 8.3.1.2.3. By End User
    • 8.3.2. Germany Neuroendocrine Tumor Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product Analysis
        • 8.3.2.2.2. By Site Analysis
        • 8.3.2.2.3. By End User
    • 8.3.3. United Kingdom Neuroendocrine Tumor Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product Analysis
        • 8.3.3.2.2. By Site Analysis
        • 8.3.3.2.3. By End User
    • 8.3.4. Italy Neuroendocrine Tumor Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product Analysis
        • 8.3.4.2.2. By Site Analysis
        • 8.3.4.2.3. By End User
    • 8.3.5. Spain Neuroendocrine Tumor Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product Analysis
        • 8.3.5.2.2. By Site Analysis
        • 8.3.5.2.3. By End User

9. North America Neuroendocrine Tumor Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product Analysis (Somatostatin Analogs (SSA), Targeted Therapy, Others)
    • 9.2.2. By Site Analysis (Lungs, Pancreas, Colon, Small Intestine, Others)
    • 9.2.3. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
    • 9.2.4. By Country
  • 9.3. North America: Country Analysis
    • 9.3.1. United States Neuroendocrine Tumor Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product Analysis
        • 9.3.1.2.2. By Site Analysis
        • 9.3.1.2.3. By End User
    • 9.3.2. Mexico Neuroendocrine Tumor Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product Analysis
        • 9.3.2.2.2. By Site Analysis
        • 9.3.2.2.3. By End User
    • 9.3.3. Canada Neuroendocrine Tumor Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product Analysis
        • 9.3.3.2.2. By Site Analysis
        • 9.3.3.2.3. By End User

10. South America Neuroendocrine Tumor Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product Analysis (Somatostatin Analogs (SSA), Targeted Therapy, Others)
    • 10.2.2. By Site Analysis (Lungs, Pancreas, Colon, Small Intestine, Others)
    • 10.2.3. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Neuroendocrine Tumor Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product Analysis
        • 10.3.1.2.2. By Site Analysis
        • 10.3.1.2.3. By End User
    • 10.3.2. Argentina Neuroendocrine Tumor Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product Analysis
        • 10.3.2.2.2. By Site Analysis
        • 10.3.2.2.3. By End User
    • 10.3.3. Colombia Neuroendocrine Tumor Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product Analysis
        • 10.3.3.2.2. By Site Analysis
        • 10.3.3.2.3. By End User

11. Middle East and Africa Neuroendocrine Tumor Treatment Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Product Analysis (Somatostatin Analogs (SSA), Targeted Therapy, Others)
    • 11.2.2. By Site Analysis (Lungs, Pancreas, Colon, Small Intestine, Others)
    • 11.2.3. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
    • 11.2.4. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa Neuroendocrine Tumor Treatment Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Product Analysis
        • 11.3.1.2.2. By Site Analysis
        • 11.3.1.2.3. By End User
    • 11.3.2. Saudi Arabia Neuroendocrine Tumor Treatment Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Product Analysis
        • 11.3.2.2.2. By Site Analysis
        • 11.3.2.2.3. By End User
    • 11.3.3. UAE Neuroendocrine Tumor Treatment Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Product Analysis
        • 11.3.3.2.2. By Site Analysis
        • 11.3.3.2.3. By End User

12. Market Dynamics

  • 12.1. Drivers
    • 12.1.1. Developments and Approval of Novel Drugs
    • 12.1.2. Use of Artificial Intelligence (AI) in Treatment Techniques
    • 12.1.3. Increased Government and Company's' Initiatives
  • 12.2. Challenges
    • 12.2.1. High Cost of the Treatment
    • 12.2.2. Associated Side Effects of the Treatment
    • 12.2.3. Stringent Regulatory Framework

13. Market Trends & Developments

  • 13.1. Upcoming Patient Assistance Programs (PAPs)
  • 13.2. Ongoing Clinical Trials and R&D Programs
  • 13.3. Adoption of Next-Generation Sequencing Techniques

14. Competitive Landscape

  • 14.1. Business Overview
  • 14.2. Company Snapshot
  • 14.3. Products & Services
  • 14.4. Financials (As Reported)
  • 14.5. Recent Developments
  • 14.6. SWOT Analysis
    • 14.6.1. F Hoffmann-La Roche AG
    • 14.6.2. Bristol-Myers Squibb Co
    • 14.6.3. Eli Lilly & Co
    • 14.6.4. Novartis AG
    • 14.6.5. Pfizer Inc
    • 14.6.6. Amgen Inc
    • 14.6.7. Exelixis Inc
    • 14.6.8. Teva Pharmaceutical Industries Ltd
    • 14.6.9. AVEO Pharmaceuticals Inc
    • 14.6.10. Hutchison MediPharma Ltd

15. Strategic Recommendations